Obesity contributes to various medical conditions, such as type 2 diabetes mellitus (T2DM), hypertension, lipid disorders, cardiovascular disease, metabolic dysfunctionassociated steatohepatitis, gallbladder disease, osteoarthritis, and certain cancers [3,4,5]
& Klein, T
As an alternative, rabbit polyclonal antibodies were generated against a segment of the murine BP180 protein homologous with the human BP180 autoantibody-reactive site and were passively transferred into neonatal BALB/c mice
Acute gallbladder disease is also labeled: cholelithiasis was reported in 1.5% of patients on 0.5 mg and 0.4% on 1 mg, and in no placebo-treated patients
2,3 REDEFINE 1 was a 68-week, double-blind, randomized, placebo- and active-controlled phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus cagrilintide 2.4 mg monotherapy, semaglutide 2.4 mg monotherapy, and placebo, all in combination with lifestyle intervention in 3,417 adults with obesity or overweight with one or more obesity-related complications and without type 2 diabetes
Allayee, W